ArticleFrontiers in medicine2025
Herbal medicines adulteration with erectile dysfunction pharmaceuticals in sub-Saharan Africa: call to strengthen regulatory measures.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sub-Saharan Africa is experiencing record levels of informal use of herbal medicines by the population for primary health care, with prevalence rates of up to 90% in some countries. This situation is linked to the high cost of pharmaceuticals and the popular perception that natural remedies are harmless. Furthermore, the proportion of men suffering from erectile dysfunction in sub-Saharan African countries remains high, varying between 25 and 70%. This dual challenge is at the root of the practice of adulterating herbal medicines with phosphodiesterase 5 inhibitors indicated for the treatment of erectile dysfunction, using abnormally high doses. This fraudulent practice poses a significant threat to consumer health, particularly for patients with comorbidities - potentially fatal erectile dysfunction, serious cardiac side effects, renal or hepatic failure, acute poisoning. This scourge is exacerbated by the weakness of regulatory systems in sub-Saharan African countries, especially their pharmacovigilance systems, which are still generally at low levels of maturity according to the WHO GBT. To combat this scourge, African countries must include the fight against pharmaceutical adulteration of herbal medicines in their policies and regulations on herbal medicines. Through their national regulatory authorities, they must develop and integrate the monitoring of herbal medicines safety into their national pharmacovigilance systems, formally involving herbalists, naturopaths and consumers. They must also develop and implement training programmes for herbalists and naturopaths in good phytotherapy practices, establish appropriate risk communication mechanisms, and ensure regular quality control of so-called natural health products sold on legal and illegal African markets, while tightening sanctions. In short, the fight against counterfeit herbal medicines must be fully integrated into the overall fight against counterfeit medicines in sub-Saharan Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.